Wang Juanjuan, Shi Qingshui, Wu Chunyong, Feng Fang
Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing 210009, China; Key Laboratory of Drug Quality Control and Pharmacovigilance, Ministry of Education, China Pharmaceutical University, Nanjing 210009, China.
Jiangsu Institute for Food and Drug Control, Nanjing 210008, China.
J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Nov 15;1036-1037:100-113. doi: 10.1016/j.jchromb.2016.10.003. Epub 2016 Oct 4.
Zhi-Zi-Da-Huang decoction (ZZDHD) has been used for treatment of alcoholic liver disease in China for thousands of years. In order to reveal the dynamic biotransformation of the decoction in vivo, a high-throughout, sensitive and special method based on high performance liquid chromatography coupled with diode array detection and time-of-flight mass spectrometry (HPLC-DAD-TOF/MS) and high performance liquid chromatography coupled with triple quadrupole mass spectrometry (HPLC-QqQ/MS) was developed and validated. 25 parent compounds and 28 metabolites were characterized, among which, two metabolites were found for the first time and tentatively identified by neutral-loss scan and product-ion scan. All the compounds were assigned to iridoids, flavones, anthraquinones, coumarin or p-coumaric acid, and their biotransformation pathways were found to involve glucuronidation, sulfation, reduction and ring cleavage. Glucuronidation occurred as a major metabolic pathway of genipin and flavanone and the conjugates could be detected almost during the whole sampling duration. To compounds such as anthraquinones, coumarin and p-coumaric acid, sulfation is the only transformation pathway and the metabolites were found at 0-12, 4-18, 4-48h respectively after administration. Reduction and/or ring cleavage of genipin glucuronide and naringin were also observed obviously. The phenomena that parts of parent compounds and metabolites were able to be detected even 48h after administration implied that the accumulating effect of these constituents in vivo would happen and the potential toxicity of the decoction might appear if multiple dosing is adopted. The strategy used in this paper was proved helpful to offer important information for the clinical safe use of ZZDHD.
栀子大黄汤(ZZDHD)在中国已被用于治疗酒精性肝病数千年。为了揭示该汤剂在体内的动态生物转化过程,开发并验证了一种基于高效液相色谱-二极管阵列检测-飞行时间质谱联用(HPLC-DAD-TOF/MS)和高效液相色谱-三重四极杆质谱联用(HPLC-QqQ/MS)的高通量、灵敏且特异的方法。鉴定出了25种母体化合物和28种代谢产物,其中,首次发现了两种代谢产物,并通过中性丢失扫描和产物离子扫描进行了初步鉴定。所有化合物被归类为环烯醚萜、黄酮、蒽醌、香豆素或对香豆酸,发现它们的生物转化途径包括葡萄糖醛酸化、硫酸化、还原和环裂解。葡萄糖醛酸化是栀子苷和黄烷酮的主要代谢途径,几乎在整个采样期间都能检测到其结合物。对于蒽醌、香豆素和对香豆酸等化合物,硫酸化是唯一的转化途径,给药后分别在0 - 12小时、4 - 18小时、4 - 48小时发现了代谢产物。还明显观察到栀子苷葡萄糖醛酸苷和柚皮苷的还原和/或环裂解。给药后48小时仍能检测到部分母体化合物和代谢产物的现象表明,这些成分在体内会发生蓄积效应,如果采用多次给药,该汤剂可能会出现潜在毒性。本文采用的策略被证明有助于为栀子大黄汤的临床安全使用提供重要信息。